London -- (MARKET WIRE) -- May 11, 2007 --

             Curidium Medica plc ("Curidium" or the "Company")


                      -  Presentation to be Webcast Live -
London, UK, 10 May, 2007, Curidium Medica plc, (LSE: CUR) today announced that it will be presenting at the Rodman & Renshaw 4th Annual Global Healthcare Conference in Monte Carlo, Monaco. Dr Anne Bruinvels, Chief Executive Officer, will be presenting the current status of the Company and its strategic business objectives. The presentation is scheduled at 5.00 pm local time on May 14th in the Meridian Beach Plaza Hotel. The presentation will be webcast and accessible remotely by persons wishing to follow the presentation live and will be archived for 30 days on the Company's website; for access please visit:

                                   -  ends  -

For further information please contact:

Anne Bruinvels +44 (0) 20 7554 8790
CEO, Curidium Medica plc

Rob Smith +44 (0) 20 7554 8793
Finance Director, Curidium Medica plc

Rhodri Cruwys / Romil Patel +44 (0) 20 7448 4400
Blue Oar Securities plc

Billy Clegg / Edward Westropp / Anna Keeble + 44 (0)20 7831 3113
Financial Dynamics

About Homomatrix®

Homomatrix® is a fully automated analysis tool that uses proprietary pattern recognition tools and sequences of mathematical algorithms together with state-of-the-art statistical methods to objectively analyze large sets of gene expression and biological data from heterogeneous populations. These analyses can potentially lead to the development of diagnostics that identify treatment-responsive patients and/or patient subgroups, signalling pathways as well as drug targets. It is anticipated that Homomatrix® could be of significant value in the drug development arena where the "most likely to respond" patients could be pre-selected to clinical trials.

About Curidium

Curidium is a company focused on identifying targeted medicines to treat patients more effectively. Through the application of its proprietary technology, Homomatrix®, Curidium analyses biological data (gene expression/protein data) from patients suffering from complex or multi- factorial diseases. Patient populations with complex disorders are known to be heterogeneous and only certain subgroups of patients respond to a specific treatment. Curidium believes that Homomatrix will ultimately allow for the development of the right drug for the right patient. The Company files patents around the genes and drug targets that are associated with the specific subgroups of patients. Further information on Curidium can be found at the Company's website:

Curidium Medica plc (c) 2002-2007. All rights reserved.
Hamilton House, Mabledon Place, London WC1H 9BB, United Kingdom.
Email: Tel.: +44 (0)20 7554 8790, 
Fax: +44 (0)20 7554 8791

                      This information is provided by RNS
            The company news service from the London Stock Exchange